Marker Therapeutics Inc (MRKR)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Peter L. Hoang |
| Employees: | 60 |
| Web site: | markertherapeutics.com |
|
2450 HOLCOMBE BLVD, SUITE BCM-A, MS: BCM251, HOUSTON, TX, 77021
(713) 400-6400
| |
-
Formally known as:
- TapImmune Inc
- TAPIMMUNE INC NEW COM STK (NV)
- TAPIMMUNE INC NEW COMMON STOCK
- TAPIMMUNE INC. NEW COMMON STOCK
| Date | Ratio |
|---|---|
| 2001-06-08 | 1:5 |
| 2007-06-28 | 10:25 |
| 2009-07-27 | 1:1 |
| 2014-02-25 | 1:100 |
| 2016-09-16 | 1:12 |
| 2023-01-27 | 1:10 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.
Please log in first to see chart